17,88 €
0,62 %
L&S, 25. September, 22:54 Uhr. Geschlossen.
ISIN
US24823R1059
Symbol
DNLI
Berichte

Denali Therapeutics Inc. Aktie News

Neutral
●
GlobeNewsWire
●
vor 3 Monaten
EN
SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) gab heute bekannt, dass Mitgründer und Chief Executive Officer Ryan Watts, Ph.D., die Eröffnungsplenarrede mit dem Titel „Accelerating the Discovery and Development of Medicines for Neurodegeneration“ auf der Alzheimer's Association International Conference® (AAIC), die vom 12. bis 15. Juli in...
Neutral
●
GlobeNewsWire
●
vor 3 Monaten
SOUTH SAN FRANCISCO, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. The U.S. Food and Drug Administration (FDA) awarded the PRV to Denali following accelerated approval of the enzyme replacement therapy...
Neutral
●
GlobeNewsWire
●
vor 5 Monaten
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2026, and provided business highlights, including the recent U.S. Food and Drug Administration (FDA) approval of AVLAYAH™ (tividenofusp alfa-eknm).
Neutral
●
GlobeNewsWire
●
vor 6 Monaten
SOUTH SAN FRANCISCO, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it has received notification from Takeda of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN). The decision was driven by strategic considerations and is not related to efficacy or safety d...
Positiv
●
Investors Business Daily
●
vor 6 Monaten
Denali Therapeutics won FDA approval Wednesday for the first new drug in 20 years to treat a rare genetic disease.
Neutral
●
GlobeNewsWire
●
vor 6 Monaten
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier and reach the whole body, including the brain. AVLAYAH is an enzyme replac...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen